--- canonical_name: Selank alternate_names: TP-7, Thr-Lys-Pro-Arg-Pro-Gly-Pro, Tuftsin analog TP-7 canonical_topic: Selank for Health & Longevity short_topic_lc: selank creation_date: 2026-0702-0134 creator_ai_fullname: Opus 4.8 --- # Selank for Health & Longevity
Evidence Review created on 07/02/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8 **Also known as:** TP-7, Thr-Lys-Pro-Arg-Pro-Gly-Pro, Tuftsin analog TP-7 ## Motivation Selank is a synthetic peptide — a short chain of seven amino acids — modeled on tuftsin, a small immune-signaling fragment the body produces naturally. It was created in Russia to calm anxiety without the drowsiness, memory dulling, and dependence that accompany conventional sedatives. Unusually, the same compound appears to sharpen focus and steady mood rather than blunt them, which is why it draws attention from people looking for a "clean" sense of calm. Selank has been approved and prescribed in Russia since 2009 for generalized anxiety, yet almost all of its research comes from Russian laboratories and small clinical studies, with little independent replication elsewhere. Outside its home country it circulates largely as an unregulated research peptide, typically used as a nasal spray. This mix of decades of use and thin international evidence is exactly what makes it interesting to examine closely. This review examines what is known about Selank: how it may work, what benefits and risks the evidence supports, how it is typically used, and where the gaps and uncertainties in the science remain. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section collects accessible, high-level overviews of Selank aimed at a knowledgeable general audience, drawn from expert commentary and practitioner writing. * [Selank Peptide Dosage, Benefits & Side Effects](https://jaycampbell.com/blog/selank-the-anti-anxiety-peptide/) - Jay Campbell A practitioner-oriented overview framing Selank as an anxiolytic and nootropic alternative to conventional sedatives, with practical discussion of dosing, expected effects, and safety caveats for an optimization-minded reader. * [My Deep Dive into Selank: The Nootropic Peptide for Anxiety, Focus, and Cognitive Performance](https://faisal798.substack.com/p/my-deep-dive-into-selank-the-nootropic) - FluxFitness A long-form personal deep dive that walks through Selank's chemistry, mechanism, and real-world use, useful for understanding how the "calm focus" profile is experienced and interpreted by end users. * [Selank: The Russian Anti-Anxiety Peptide That Doubles as a Nootropic](https://chameleonpeptides.com/2026/03/10/selank-comprehensive-research-review-of-the-anxiolytic-nootropic-peptide/) - Stuart Ratcliff & Kai A structured research-oriented overview summarizing the GABAergic (relating to GABA, the brain's main calming signal) modulation, BDNF (brain-derived neurotrophic factor, a protein that supports the growth and survival of neurons), and enkephalin mechanisms and the animal-model evidence base, with an emphasis on what has and has not been demonstrated. * [Selank Peptide: Benefits, Dosage & Why It's the Best Anti-Anxiety Nootropic](https://www.peptidedeck.com/blog/selank-peptide-guide) - PeptideDeck A concise consumer-facing guide summarizing benefits, dosing ranges, and administration routes, helpful for a quick orientation to how Selank is typically used in practice. * [Selank: Complete Guide to the Anti-Anxiety Peptide](https://thepeptideindex.com/post/selank-complete-guide-anti-anxiety-peptide) - The Peptide Index A broad guide covering the science, protocol timelines, and stacking considerations, giving context on how Selank is positioned relative to benzodiazepines and other anxiety approaches. ## Grokipedia * [Selank](https://grokipedia.com/page/Selank) - Grokipedia A dedicated encyclopedia entry covering Selank's structure, development history, Russian regulatory approval, mechanism, and clinical and preclinical evidence, useful as a broad orientation to the compound. ## Examine No dedicated Examine.com article for Selank was found. Examine.com focuses on dietary supplements and nutrients with a substantial evidence base and does not typically cover investigational research peptides such as Selank. ## ConsumerLab No ConsumerLab article or product test for Selank was found. ConsumerLab independently tests commercially marketed consumer supplements and does not cover investigational research peptides such as Selank, which are not sold as regulated dietary supplements. ## Systematic Reviews No systematic reviews or meta-analyses for Selank were found on PubMed as of 07/02/2026. ## Mechanism of Action Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide (seven-amino-acid chain) built by adding a stabilizing Pro-Gly-Pro tail to tuftsin, a naturally occurring immune-signaling fragment. Its biological effects are attributed to several overlapping mechanisms, though most have been characterized in animal or cell models rather than in humans. * **GABAergic modulation:** Selank appears to act as a positive allosteric modulator (a compound that gently tunes a receptor's response rather than switching it fully on) of the GABA-A receptor — the brain's main "braking" system that calms neural activity. Radioligand-binding work shows Selank alters GABA binding and can modify the effects of benzodiazepines (a class of sedatives such as diazepam) without simply mimicking them, which is proposed to explain its calming effect without heavy sedation. * **Enkephalin stabilization:** Selank inhibits enkephalin-degrading enzymes (enzymes that break down the body's natural opioid-like "feel-good" peptides). By slowing this breakdown it raises and prolongs enkephalin activity, which is one proposed route to its anti-anxiety and mood effects. This was demonstrated in human blood plasma as well as animal tissue. * **Monoamine and BDNF effects:** In animals Selank influences serotonin and dopamine turnover (brain chemicals governing mood, motivation, and focus) and raises brain-derived neurotrophic factor, BDNF (a protein that supports the growth and survival of neurons), particularly in the hippocampus and prefrontal cortex — regions tied to memory and executive function. These are proposed to underlie its cognitive ("nootropic") and antidepressant-like effects. * **Immune and inflammatory signaling:** Retaining tuftsin-like activity, Selank modulates the balance of Th1/Th2 cytokines (signaling molecules that steer the immune response) and the expression of inflammation-related genes, which is the basis for its claimed immunomodulatory and adaptogenic properties. Where mechanistic explanations compete, the picture is unsettled: some work frames the GABA-A interaction as central, while other lines emphasize enkephalin-system and monoamine effects as primary, and the relative contribution of each in humans is not established. **Key pharmacological properties:** Selank is a peptide and is not metabolized by the cytochrome P450 (CYP) liver-enzyme system that handles most small-molecule drugs; instead it is broken down by peptidases into shorter fragments, several of which retain activity. Its intact plasma half-life is very short (on the order of minutes), but its behavioral effects last far longer — reportedly hours to days after a dose — attributed to active metabolites and downstream gene-expression changes. It is not orally bioavailable in a meaningful way (peptides are digested), so it is given intranasally or by injection; intranasal delivery is proposed to allow some direct nose-to-brain transport. ## Historical Context & Evolution * **Original development:** Selank was developed in the early 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences, in collaboration with what is now the Zakusov Institute of Pharmacology, as a deliberately engineered stable analog of tuftsin. Tuftsin itself is an endogenous immune-modulating peptide with anxiolytic and nootropic properties in animals but is too short-lived to be a practical drug; adding the Pro-Gly-Pro tail was intended to slow enzymatic breakdown while preserving activity. * **Path to health optimization use:** The original intended use was as an anxiolytic (anti-anxiety agent) that could rival benzodiazepines without their sedation, memory impairment, and dependence. Early Russian studies reported that it not only reduced anxiety but also improved learning and mood, which broadened interest toward cognitive enhancement, stress resilience, and immune support — the properties that later attracted the peptide-optimization community outside Russia. * **Findings, not just reception:** Preclinical work reported dose-dependent inhibition of enkephalin-degrading enzymes, allosteric effects on GABA-A binding, increased hippocampal BDNF, and shifts in inflammation-related gene expression. Small Russian clinical studies in anxiety and asthenic (fatigue-and-weakness) disorders reported reduced anxiety scores and a favorable tolerability profile, including when Selank was combined with benzodiazepines to reduce their side effects. * **Standing of the evidence:** Selank has not been "debunked," but neither has its early promise been independently confirmed. Its approval and nearly all of its human data originate from Russia, and the clinical trials are small, often not blinded to modern standards, and rarely replicated by independent Western groups. The evolution of opinion is therefore less a shift in consensus than a persistent gap: enthusiasm in the peptide-use community versus caution from the broader scientific community, which regards the human evidence as preliminary. What would change this is independent, adequately powered, placebo-controlled trials, which have not yet been published. ## Expected Benefits ### Medium 🟩 🟩 #### Anxiety Reduction Selank's best-supported benefit is reduction of anxiety. Its proposed mechanism combines positive allosteric modulation of GABA-A receptors with stabilization of the body's natural enkephalins, producing a calming effect described as occurring without the sedation or cognitive dulling of benzodiazepines. The evidence includes several small Russian clinical studies in generalized anxiety and phobic-anxiety disorders — including a randomized comparison with the benzodiazepine phenazepam — reporting comparable anxiolytic effect with better tolerability, plus consistent animal data. The main limitation is that these trials are small, single-region, and not independently replicated, so the grade reflects genuine but low-certainty human signal for this specific target audience. **Magnitude:** In small clinical studies, anxiety-scale reductions were reported as comparable to the benzodiazepine phenazepam, with the effect reportedly persisting up to roughly a week after the last dose; exact effect sizes are not robustly established. #### Cognitive Enhancement (Nootropic Effect) Selank is reported to improve attention, learning, and mental clarity, an unusual pairing with its calming effect. The proposed mechanism involves raised BDNF in the hippocampus and prefrontal cortex and modulation of serotonin and dopamine turnover. Evidence is stronger in animals (improved learning and memory, especially in animals with initially poor performance) than in humans, where nootropic effects appear mainly as mild secondary observations within the anxiety trials rather than as primary endpoints. The benefit is plausible and consistent across preclinical data but under-tested as a stand-alone human outcome. **Magnitude:** Not quantified in available studies. ### Low 🟩 #### Mood Support and Antidepressant-Like Effect Beyond anxiety, Selank is reported to lift low mood, attributed to enkephalin stabilization and effects on serotonin and dopamine systems. Animal models of depression show antidepressant-like behavioral effects, and human anxiety studies noted improvements in mood and quality of life. However, no dedicated human trials in depression exist, the human data are secondary, and the effect is not separable from the anxiety improvement, so certainty is low. **Magnitude:** Not quantified in available studies. #### Immune Modulation As a tuftsin analog, Selank retains immune-signaling activity and is reported to rebalance Th1/Th2 cytokines and influence inflammation-related gene expression. A small human study in anxiety-asthenic patients reported cytokine changes suggestive of immunomodulation, and animal work shows shifts in inflammatory gene expression. This is proposed as an "adaptogenic" benefit potentially relevant to stress-related immune suppression, but human evidence is minimal and no clinical endpoints (e.g., infection rates) have been demonstrated. **Magnitude:** Not quantified in available studies. #### Stress Resilience and Physiological Protection Selank is reported to buffer the physiological consequences of chronic stress. Animal studies under chronic restraint or foot-shock stress report protective effects on liver function, gut-lining structure, gut microbiota composition, and cytokine profiles. This broad "adaptogenic" protection is biologically coherent with its stress-modulating and anti-inflammatory actions but rests almost entirely on rodent models with no direct human confirmation. **Magnitude:** Not quantified in available studies. ### Speculative 🟨 #### Metabolic and Hemostatic Effects A small number of animal studies report that Selank can favorably influence blood sugar, lipid profile, and clotting parameters in models of metabolic syndrome, and that related glyproline peptides have mild anticoagulant activity. These findings are isolated, mechanistically preliminary, and derive solely from rodent experiments with no human data, so any relevance to metabolic health or longevity in people is purely hypothetical at this stage. #### Longevity and Healthspan No direct evidence links Selank to extended lifespan or healthspan in any species. The longevity rationale is entirely indirect and mechanistic: chronic anxiety, dysregulated stress physiology, low BDNF, and chronic inflammation are each associated with worse long-term health, and Selank plausibly touches all of these. This chain of reasoning is speculative, with no controlled aging or hard-outcome studies of any kind. ## Benefit-Modifying Factors * **Baseline anxiety level:** The clearest benefit appears in people with elevated anxiety; effects in already-calm individuals are less evident. Animal work notably showed cognitive gains concentrated in subjects with initially poor performance, suggesting Selank may normalize a dysregulated baseline more than it enhances an optimal one. * **Baseline enkephalin and stress-system state:** Because a proposed mechanism is stabilizing enkephalins and dampening an over-active stress response, individuals with a more dysregulated baseline (high chronic stress, low endogenous opioid tone) may notice more benefit, whereas those with balanced stress physiology may notice little. * **Concurrent benzodiazepine use:** Human studies suggest Selank's value is amplified as an add-on to benzodiazepines, where it improved outcomes and reduced the sedative's side effects; benefit as a stand-alone agent, while reported, is less firmly established. * **Pre-existing health conditions:** Benefit is characterized only in anxiety and stress-related and asthenic conditions. Its relevance to people without these conditions — the healthy-optimizer use case — is inferred, not demonstrated. * **Sex-based differences:** No human data isolate sex-based differences in Selank response. Preclinical studies use predominantly male animals, so sex-specific efficacy in humans is unknown. * **Age-related considerations:** One human study specifically suggested Selank's adaptogenic and immune effects might benefit older adults and those under environmental stress, but this was not tested in a dedicated older-adult trial, so age-specific efficacy — including at the older end of the target range — remains unconfirmed. ## Potential Risks & Side Effects ### Low 🟥 #### Generally Mild, Transient Adverse Effects Across the available (predominantly Russian and small) clinical studies, Selank is consistently described as well tolerated, with a favorable side-effect profile relative to benzodiazepines and no reported dependence or withdrawal. The most commonly noted effects are mild and transient. The key caveat is that this reassuring profile rests on small, short-duration studies without rigorous long-term safety surveillance, so absence of reported harm is not the same as demonstrated long-term safety. **Magnitude:** In small studies, adverse effects were infrequent and mild; no serious drug-related adverse events were reported, though sample sizes were too small to detect uncommon harms. #### Nasal and Local Irritation (Intranasal Route) Because Selank is most often given as a nasal spray, the most practically relevant side effects are local: nasal irritation, dryness, stinging, or a transient unpleasant taste. These reflect the delivery route rather than the peptide's systemic action and are generally minor and self-limiting, but they are the effects a typical user is most likely to encounter. **Magnitude:** Not quantified in available studies. ### Speculative 🟨 #### Unknown Long-Term and Immune Effects Selank's immune-modulating activity is presented as a benefit, but chronic modulation of cytokine balance and inflammatory signaling has no long-term human safety data. Sustained shifts in immune signaling could in principle be undesirable in some individuals (e.g., those with autoimmune conditions), but this is a theoretical concern extrapolated from mechanism, not an observed harm. #### Product Quality and Contamination Risks Outside Russia, Selank is sold almost exclusively as an unregulated "research chemical," not a pharmaceutical or dietary supplement. The dominant real-world risk is therefore not the peptide itself but the product: incorrect dosing, degradation, bacterial contamination (a particular concern for injectable or reconstituted material), and undisclosed impurities. This is a supply-chain risk rather than a demonstrated pharmacological effect, hence speculative as a property of Selank, but practically important. #### Additive Central Nervous System Effects Given GABAergic activity, combining Selank with other sedating or GABA-active substances could theoretically compound central nervous system effects. Human data specifically show interaction with benzodiazepines (used deliberately to reduce their side effects), but the safety of combinations with alcohol, other sedatives, or additional GABAergic compounds is not characterized. ## Risk-Modifying Factors * **Genetic polymorphisms:** No pharmacogenetic data exist for Selank. Because it is peptidase-metabolized rather than CYP-metabolized, common drug-metabolism gene variants (e.g., CYP2D6 and CYP3A4, liver enzymes that break down many small-molecule drugs) are unlikely to be relevant, but this has not been formally studied. * **Baseline immune status:** Individuals with autoimmune or inflammatory conditions may theoretically be more sensitive to Selank's cytokine-modulating effects; this is a mechanistic caution, not an established risk factor, and warrants conservative consideration in such populations. * **Sex-based differences:** No human data characterize sex-based differences in Selank's side effects. Preclinical safety work is predominantly in male animals. * **Pre-existing health conditions:** Risk has been characterized only in relatively healthy anxiety-disorder patients. People with significant psychiatric, immune, or other chronic conditions were not represented, so the side-effect profile in those groups is unknown. * **Age-related considerations:** No dedicated safety data exist for older adults despite suggestions of benefit in that group; age-related differences in tolerability, including at the older end of the target range, are unstudied. * **Product source and route:** The largest modifiable risk factor is product quality and administration route — unregulated sourcing and injectable use raise contamination and dosing risks far more than the peptide's intrinsic pharmacology. ## Key Interactions & Contraindications * **Benzodiazepines (diazepam, phenazepam, alprazolam):** Documented interaction — additive/modifying. In human and animal studies Selank was combined with benzodiazepines and altered their effect, reducing benzodiazepine side effects while maintaining anxiolysis. Severity: caution/monitor. Consequence: potentiated or modified central nervous system effects. Mitigating action: use combinations only under clinical supervision with attention to sedation. * **Other GABA-active or sedating drugs (barbiturates, "Z-drugs" such as zolpidem, gabapentinoids):** Theoretical additive central nervous system depression given Selank's GABAergic activity. Severity: caution. Consequence: possible excess sedation. Mitigating action: avoid unmonitored stacking; separate introduction to observe effects. * **Alcohol and other over-the-counter sedatives (e.g., antihistamines such as diphenhydramine):** Over-the-counter sedating agents and alcohol could theoretically add to central nervous system effects; notably, animal studies show Selank interacts with alcohol-related behaviors and may protect against alcohol-induced memory impairment, but combined human safety is uncharacterized. Severity: caution. Consequence: unpredictable sedation or interaction. Mitigating action: avoid concurrent use pending data. * **Antidepressants and other serotonergic/dopaminergic agents:** Because Selank affects serotonin and dopamine turnover, theoretical additive effects with antidepressants (e.g., SSRIs, or selective serotonin reuptake inhibitors — a common class of antidepressants such as sertraline) cannot be excluded. Severity: caution. Consequence: unknown; monitor for mood or activation changes. Mitigating action: clinical oversight if combined. * **Supplement interactions (additive):** Supplements with calming/GABAergic or serotonergic activity — e.g., L-theanine, magnesium, valerian, kava, 5-HTP, or high-dose glycine — could be additive with Selank's anxiolytic effect. Consequence: enhanced sedation/calming; generally low severity but relevant when stacking. * **Immunomodulatory agents:** Given tuftsin-like immune activity, combining Selank with other immunomodulators or immunosuppressants is theoretically capable of additive or opposing effects. Severity: caution. Consequence: unpredictable immune effects. Mitigating action: avoid in those on immune-modifying therapy without oversight. * **Populations who should avoid Selank:** Pregnant or breastfeeding individuals (no safety data); people with autoimmune or significant immune-mediated conditions (theoretical immune modulation); individuals with serious psychiatric illness managed with multiple central nervous system agents; and anyone unable to verify product quality. Because Selank is not an approved drug outside Russia and lacks pediatric, pregnancy, and chronic-use safety data, its use in these groups has no supporting evidence. ## Risk Mitigation Strategies * **Verify product identity and purity:** Because the dominant risk is unregulated sourcing, product obtained with a certificate of analysis confirming identity and purity plus third-party testing for contaminants directly mitigates the risks of mislabeled dose, degradation, and impurity exposure described in the Risks section. * **Prefer intranasal over injectable use:** Use of the intranasal route over reconstituted injectable material mitigates the bacterial-contamination and injection-site risks that are the most consequential practical hazards; where injection is used, strict sterile technique and single-use vials are essential. * **Start low and assess individually:** Starting at the low end of typical protocols (e.g., a single low daily intranasal dose) and observing response before any escalation mitigates the risk of additive central nervous system effects and unexpected individual sensitivity. * **Avoid unmonitored central nervous system stacking:** Avoiding simultaneous combination of Selank with alcohol, sedatives, or multiple GABAergic supplements mitigates the risk of compounded sedation and the unpredictable interactions identified in Interactions. * **Limit duration and reassess:** Given the absence of long-term human safety data, time-limited courses (e.g., 2–4 weeks) with reassessment rather than indefinite continuous use mitigate the speculative long-term immune and unknown chronic-exposure risks. * **Screen for immune and psychiatric conditions:** Accounting beforehand for autoimmune conditions, pregnancy, and complex psychiatric medication regimens — the populations flagged to avoid — mitigates the risk of immune modulation or drug interactions in vulnerable individuals. ## Therapeutic Protocol * **Standard approach (Russian clinical use):** As used in Russian clinical practice, Selank is administered as a 0.15% intranasal solution, with typical daily doses in the range of roughly 250–3,000 micrograms (commonly cited as about 2–4 drops per nostril, one to three times daily), given in courses of about 10–14 days. This regimen underlies the anxiety and asthenic-disorder studies and is the closest thing to a validated protocol. * **Competing approaches (integrative/optimization use):** Outside clinical medicine, the peptide-optimization community typically uses intranasal Selank at similar or somewhat higher daily totals (often cited around 300–900 micrograms/day, sometimes up to ~3,000 micrograms), self-administered in cycles. Neither the clinical nor the optimization approach is framed here as definitive; the clinical regimen has study support, while community protocols are experience-based and not validated. * **Practitioners and origin:** The intranasal clinical protocol traces to the developing institutions — the Institute of Molecular Genetics and the Zakusov Institute of Pharmacology (Russian Academy of Sciences), with clinical work led by groups including Medvedev and colleagues; optimization protocols are popularized largely by peptide-focused clinicians and writers rather than a single authority. * **Best time of day:** Dosing is generally split across the day (e.g., morning and midday) rather than at night, since Selank is reported to be non-sedating and mildly stimulating in some users; timing earlier in the day is preferred to avoid any activation near sleep. * **Half-life considerations:** The intact peptide's plasma half-life is very short (minutes), but behavioral effects reportedly persist for hours to days owing to active metabolites and downstream effects — one reason short courses can produce lasting effects and why anxiety benefit was reported to persist after stopping. * **Single vs. split dosing:** Because of the short intact half-life but prolonged downstream effect, protocols typically use split daily dosing (two to three times daily) rather than a single dose, to maintain steady exposure across waking hours. * **Genetic polymorphisms:** No pharmacogenetic guidance exists. As a peptidase-metabolized peptide, Selank dosing is not expected to hinge on common CYP variants (e.g., CYP2D6, CYP3A4) or on APOE (a gene affecting fat transport and brain aging risk), MTHFR (a gene for an enzyme in folate and homocysteine processing), or COMT (a gene for an enzyme that clears dopamine and related signals) status, but this has not been studied and no dose adjustment is defined. * **Sex-based differences:** No sex-specific dosing has been established; trials did not report dose differences by sex, and preclinical work is predominantly male. * **Age-related considerations:** No age-specific dosing is defined. Suggestions of benefit in older adults were not paired with dose-finding, so conservative low-dose starting is reasonable at the older end of the target range in the absence of data. * **Baseline biomarkers:** No biomarker is validated to guide dosing. Where an immune or inflammatory rationale is invoked, baseline markers such as CRP (C-reactive protein, a general marker of inflammation) or a cytokine panel are sometimes checked, but these do not have established dose-response value for Selank. * **Pre-existing conditions:** Dosing was studied in anxiety and asthenic-disorder patients; there is no protocol for people with major psychiatric, immune, or other chronic conditions, who fall outside the evidence base. ## Discontinuation & Cycling * **Lifelong vs. short-term:** Selank is designed for short-term, course-based use (typically ~10–14 day courses) rather than continuous lifelong administration; the human evidence base covers only short courses, and there is no support for indefinite use. * **Withdrawal effects:** No withdrawal syndrome has been reported. A central selling point in the clinical literature is that, unlike benzodiazepines, Selank produced no dependence or withdrawal in the studies conducted, and its anxiolytic effect reportedly persisted for about a week after stopping. * **Tapering:** Because no dependence or withdrawal has been observed, no tapering protocol is described or considered necessary; courses are simply stopped at completion. This reflects the absence of observed withdrawal rather than long-term proof of safety. * **Cycling:** Cycling (courses separated by off-periods) is the norm both in clinical use and in optimization protocols, consistent with its course-based design and the reported carry-over of effect after stopping. There is no evidence that continuous use maintains or improves efficacy over cycled use, and cycling is generally preferred given the lack of long-term data. * **Practical discontinuation:** In practice, users complete a defined course and reassess after an off-period, resuming only if the earlier benefit was clear; this course-and-reassess pattern is the de facto discontinuation strategy. ## Sourcing and Quality * **Regulatory reality:** Selank is an approved pharmaceutical only in Russia (and some neighboring countries); elsewhere it is sold as an unregulated "research chemical," meaning no pharmacopeial quality standards apply and product quality is the single most important sourcing concern. * **What to look for:** Prioritize suppliers providing a recent certificate of analysis (COA) with identity confirmation (e.g., mass spectrometry) and quantified purity (ideally ≥98%), plus independent third-party testing for sterility and endotoxin where relevant — these directly address the mislabeling and contamination risks. * **Formulation:** Intranasal solutions (the form used clinically) are generally preferable to self-reconstituted lyophilized (freeze-dried) powder for injection, which introduces sterility and dosing-accuracy challenges; if using powder, correct reconstitution and cold storage matter. * **Reputable options:** There are no regulated Western brands. In Russia, Selank is marketed as a registered nasal-spray pharmaceutical; outside Russia, only research-chemical suppliers exist, and even those that third-party test cannot substitute for pharmaceutical-grade regulation. Compounding pharmacies in some jurisdictions may prepare peptides, but availability and legality vary. * **Storage and handling:** Peptides are sensitive to heat and degradation; reputable practice is refrigerated storage, protection from light, and use within the supplier's stated stability window to prevent loss of potency or breakdown-product accumulation. ## Practical Considerations * **Time to effect:** Some users report acute calming within hours of a dose, but the more consistent pattern in the literature is subtle onset over 1–3 days, with noticeable anxiety reduction and improved focus over roughly 1–2 weeks of a course; cognitive effects tend to build over the course rather than appear immediately. * **Common pitfalls:** Frequent mistakes include using unverified research-chemical product, over-dosing in pursuit of a stimulant-like effect (Selank's effect is subtle, not dramatic), expecting benzodiazepine-like acute relief, injecting reconstituted powder without sterile technique, and continuous long-term use despite the absence of long-term safety data. * **Regulatory status:** Selank is a prescription pharmaceutical in Russia but is not approved by the FDA or EMA; in most Western countries it is neither an approved drug nor a legal dietary supplement, and is sold only labeled "for research use, not for human consumption." Personal use therefore sits in a legal grey area and is entirely off-label/unapproved. * **Cost and accessibility:** Selank is relatively inexpensive as research peptides go, but accessibility outside Russia is limited to unregulated online suppliers, and reliable, quality-assured product is the main access barrier rather than price. ## Interaction with Foundational Habits * **Sleep:** Direction — indirect/potentiating on sleep quality. By reducing anxiety without sedation, Selank may indirectly improve sleep in anxious individuals; however, because some users find it mildly activating, dosing is best kept to earlier in the day to avoid interfering with sleep onset. No direct effect on sleep architecture has been demonstrated. * **Nutrition:** Direction — largely none/indirect. No specific dietary requirement or nutrient depletion is established for Selank. As an intranasal peptide it is not meaningfully affected by food, and no diet is required to be paired with it; any interaction is indirect via general stress and metabolic health. * **Exercise:** Direction — indirect. No evidence indicates Selank blunts or enhances training adaptations such as hypertrophy. Its potential relevance to exercise is indirect — through reduced anxiety and improved stress resilience and focus — rather than any demonstrated effect on performance or recovery, and there is no established timing relative to workouts. * **Stress management:** Direction — direct/potentiating. This is the habit domain most aligned with Selank's proposed effects: it directly targets the stress and anxiety axis (via GABAergic and enkephalin mechanisms) and animal studies show protection against the physiological damage of chronic stress. It is best viewed as a potential complement to — not a replacement for — foundational stress-management practices such as sleep, exercise, and behavioral techniques. ## Monitoring Protocol & Defining Success Because Selank is used for anxiety, mood, and stress-related goals, monitoring is primarily clinical and qualitative, supported by a small set of optional labs where an immune or metabolic rationale is invoked. Baseline assessment before starting establishes a reference point, and periodic reassessment gauges whether the intended benefit is materializing. Baseline testing should include documenting current anxiety and mood status (ideally with a simple standardized self-rating) and, where an immune or metabolic rationale is being pursued, optional baseline inflammatory and metabolic markers. Given the absence of validated Selank-specific biomarkers, these labs are supportive context rather than required gating tests. Ongoing monitoring is best structured around the course: reassess subjective anxiety, mood, focus, and sleep at roughly 1 week and at the end of a 2–4 week course, then again after an off-period before deciding whether to repeat; optional labs, if used, can be rechecked every 3–6 months only if there is a specific reason. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | | --- | --- | --- | --- | | hs-CRP (high-sensitivity C-reactive protein) | < 1.0 mg/L | Tracks systemic inflammation, relevant if pursuing an anti-inflammatory/adaptogenic rationale | Fasting not required; avoid testing during acute illness or injury, which transiently raises it. Conventional "normal" extends to 3.0 mg/L, but functional target is < 1.0 | | Fasting glucose | 70–85 mg/dL | Context for the speculative metabolic-syndrome findings | Requires 8–12 h fasting; best drawn in the morning. Conventional range extends to 99 mg/dL | | Fasting insulin | 2–5 µIU/mL | Metabolic context if a metabolic rationale is being pursued | Requires fasting; pair with glucose to assess insulin sensitivity. Conventional labs often flag only > 25 µIU/mL | | Lipid panel (total, LDL, HDL, triglycerides) | Triglycerides < 80 mg/dL; HDL > 50 mg/dL | Context for reported lipid effects in animal metabolic-syndrome models | 9–12 h fasting typically requested; best paired with glucose/insulin drawn the same morning | Qualitative markers are the primary success measures for Selank: * Reduction in day-to-day anxiety and a sense of calm without sedation * Improved focus, mental clarity, and freedom from "brain fog" * Stable or improved mood * Sleep quality (improved indirectly via lower anxiety; not disrupted) * Subjective stress resilience — feeling less reactive to stressors ## Emerging Research * **Sparse registered-trial landscape:** No active clinical trials of Selank are registered on ClinicalTrials.gov as of this review; because Selank's development and approval are Russia-based, any ongoing structured research is likely registered in Russian systems and not indexed in Western registries, which is itself a notable gap. * **Mechanistic neuroimaging:** A functional-connectivity line of work has examined how Selank and the related peptide Semax affect brain network connectivity, moving beyond behavioral endpoints toward objective imaging measures ([Panikratova et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32342318/)). Direction — could strengthen the case by providing an objective biomarker of central effect. * **GABAergic and gene-expression mechanisms:** Ongoing preclinical work continues to characterize Selank's allosteric modulation of GABA-A receptors and its effects on the expression of neurotransmission-related genes ([Volkova et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26924987/)). Direction — refines (and could either support or complicate) the proposed mechanism. * **Stress-protection and gut/microbiome effects:** A cluster of rodent studies on chronic stress has extended into gut microbiota and intestinal-structure protection ([Mukhina et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31236882/)). Direction — could broaden the "adaptogenic" rationale but remains far from human validation and could equally fail to translate. * **Addiction and withdrawal applications:** Newer animal work explores Selank in morphine-withdrawal and alcohol-related models ([Konstantinopolsky et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36322304/)). Direction — an emerging therapeutic direction that could expand indications, though it is preliminary and in animals. * **Future research that could change understanding:** The decisive open question is whether independent, adequately powered, placebo-controlled human trials — conducted outside the originating institutions — can replicate the reported anxiolytic and nootropic effects and establish long-term safety. Evidence that could weaken the case includes failure to replicate the small Russian trials or discovery of long-term immune or other harms; evidence that could strengthen it includes objective neuroimaging biomarkers and confirmed human efficacy. Until such studies exist, the human evidence base remains preliminary and single-region. ## Conclusion Selank is a synthetic peptide developed in Russia and used there since 2009 to ease anxiety. Its appeal is an unusual combination: calming effects that, in the available studies, come without the drowsiness, memory dulling, or dependence linked to conventional sedatives, alongside modest gains in focus, mood, and stress resilience. Proposed actions include tuning the brain's main calming system and slowing the breakdown of the body's own feel-good peptides, together with effects on immune signaling. The central limitation is the evidence itself. Nearly all human data come from small studies in Russia, tied to the groups that developed the compound, and have not been independently repeated. Its calming effect is the best supported; cognitive, mood, immune, and stress-protection benefits rest mostly on animal work, and any link to long-term health or longevity is purely theoretical. Reported safety is reassuring but comes from short, small studies rather than long-term monitoring, and outside Russia the compound is sold unregulated, making product quality a real-world concern in its own right. Selank is best understood as a promising but under-proven compound: decades of use and a coherent mechanism on one side, thin and unreplicated human evidence on the other. What is genuinely known and what is merely plausible remain far apart, and that gap is the defining feature of the current picture. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**